AXL as a Target in Breast Cancer Therapy

Abstract EN

AXL is a receptor tyrosine kinase (RTK) that has been implicated in diverse tumor-promoting processes such as proliferation, migration, invasion, survival, and apoptosis.

AXL therefore plays a role in cancer progression, and AXL has been implicated in a wide variety of malignancies from solid tumors to hematopoietic cancers where it is often associated with poor prognosis.

In cancer, AXL has been shown to promote epithelial to mesenchymal transition (EMT), metastasis formation, drug resistance, and a role for AXL in modulation of the tumor microenvironment and immune response has been identified.

In light of these activities multiple AXL inhibitors have been developed, and several of these have entered clinical trials in the U.S.

In breast cancer, high levels of AXL expression have been observed.

The role of AXL in cancer with a focus on therapeutic implications for breast cancer is discussed.